 |
|
| Blog results | Results 1 - 10 of about 354,945 for phase iii. (0.15 seconds) |
| Sorted by relevance Sort by date |
| Related Blogs: | Phase III - Stealth is. - http://www.stealthisknowledge.com/ Watch Us Grow - http://alexandriaphasethree.blogspot.com/ The System - http://www.alphaintime.com/ Sleepy Brain: Goodnight & God Bless - http://www.sleepybrain.net/ | |
| 7 hours ago Dec 15, 2009 - Gilead Sciences, Inc. (Nasdaq GILD) today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company s end. Drugs.com - Pharma News - http://www.drugs.com/news.html |
| 20 hours ago by Business Wire FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's. Your Story - http://www.your-story.org/ [ More results from Your Story ] |
| 6 hours ago by MedicalReplies MedicalReplies.com - Gilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant ... Medical Replies - Medical News And Articles - http://medicalreplies.com/ |
| 1 hour ago by DoctorFrog Gilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor. Procto-Med - http://www.procto-med.com/ [ More results from Procto-Med ] |
| 9 hours ago by admin LONDON (MarketWatch) -- Gilead Sciences Inc. said Tuesday that a Phase III clinical trial evaluating darusentan did not achieve its co-primary efficacy. Insider Stock News - http://www.insiderstocknews.com/ |
| 10 Dec 2009 SOLID-TIMI 52 is the second pivotal Phase III trial to evaluate darapladib. The first large-scale trial, STABILITY, is studying darapladib in patients with chronic coronary artery disease. STABILITY was initiated in late 2008 and has ... PharmaNews.eu - http://www.pharmanews.eu/component/content/frontpage - References [ More results from PharmaNews.eu ] |
| 14 Dec 2009 by pharmafeed A late-stage study of Roche's rheumatoid arthritis drug ocrelizumab has hit its primary endpoint in a group of hard-to-treat patients. The drug combined. PharmaFeed - http://www.pharmafeed.com/ [ More results from PharmaFeed ] |
| 10 Dec 2009 by nobody@flickr.com (US Coast Guard) CG Portal Phase III. ... CG Portal Phase III. CG Portal Phase III by U.S. Coast Guard. To take full advantage of Flickr, you should use a JavaScript-enabled browser and install the latest version of the Macromedia Flash Player. ... Uploads from US Coast Guard - http://www.flickr.com/photos/coast_guard/ |
| 10 Dec 2009 Treatment with once-monthly INVEGA SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL CONSTA , according to new data from a comparative study of. Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html - References [ More results from Drugs.com - Clinical Trials ] |
| 4 hours ago by mjames According to the results of two Phase III clinical trials, the addition of AvastinŽ (bevacizumab) to first- or second-line chemotherapy delays cancer progression but may not improve overall survival among women with advanced breast ... CancerConsultants - http://www.cancerconsultants.com/ [ More results from CancerConsultants ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
